Patents Examined by Maryam Monshipouri
-
Patent number: 11965184Abstract: Engineered Cas9 systems are disclosed herein.Type: GrantFiled: February 10, 2021Date of Patent: April 23, 2024Assignee: Sigma-Aldrich Co. LLCInventor: Fuqiang Chen
-
Patent number: 11959073Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.Type: GrantFiled: April 29, 2021Date of Patent: April 16, 2024Assignee: SEATTLE CHILDREN'S RESEARCH INSTITUTEInventors: Andrew M. Scharenberg, Michael T. Certo, Kamila Sabina Gwiazda
-
Patent number: 11959112Abstract: Cotton-containing textiles, such as “trash” feedstock in terms of end-of-life-cotton textiles, may be used to produce sugar without the same kinds of harsh pretreatments used for other biomasses, such as corn, grass sources, or wood. Disclosed is a process for production of sugar from a cotton-containing textile waste fabric comprising optionally mechanically pretreating the cotton-containing textile, pretreating the cotton-containing textile with an acid pretreatment to form a slurry, cooling the slurry, adding at least one base to the slurry, adding at least one additional acid to the slurry to form a buffer in situ, adding a hydrolysis enzyme, and optionally filtering the slurry.Type: GrantFiled: May 20, 2022Date of Patent: April 16, 2024Assignee: COTTON INCORPORATEDInventors: Matthew J. Farrell, Sha Fu, Mary A. Ankeny
-
Patent number: 11952398Abstract: A chromatographic method for collecting blood coagulation factor VII (Factor VII) and/or activated blood coagulation factor VII (activated Factor VII) from plasma-derived fractions with high yield is provided. In accordance with the method of the present invention, Factor VII and/or activated Factor VII of interest can be collected with a recovery rate of as high as 90% or more by letting Factor VII and/or activated Factor VII which fails to be adsorbed to a first anion exchange resin and remains in a non-adsorption fraction be adsorbed in a second anion exchange resin.Type: GrantFiled: June 9, 2021Date of Patent: April 9, 2024Assignee: KM Biologics Co., Ltd.Inventors: Kentaro Ebisu, Takashi Kai, Nozomi Matsuo
-
Patent number: 11946080Abstract: Disclosed herein is one or more subtilisin variants, nucleic acids encoding same, and compositions and methods related to the production and uses thereof, including one or more subtilisin variants that has improved stability and/or soil removal compared to one or more reference subtilisin.Type: GrantFiled: June 18, 2017Date of Patent: April 2, 2024Assignee: DANISCO US INC.Inventors: Richard R. Bott, David A. Estell, Frits Goedegebuur, Harm Mulder, Sina Pricelius
-
Patent number: 11946197Abstract: The present disclosure relates to a method for modifying polyester by a swelling agent combined with cutinase, belonging to the technical field of textile processing. According to the method, a phenol solution or an o-vanillin solution is used as the swelling agent to perform swelling treatment on the polyester, and combined with a Humicola insolens cutinase solution to perform hydrophilic modification on the polyester, which not only significantly improves the release amount of hydrolysates, but also reduces the fabric mass loss compared with the traditional chemical modification method.Type: GrantFiled: July 27, 2023Date of Patent: April 2, 2024Assignee: JIANGNAN UNIVERSITYInventors: Jiajia Fu, Jundan Feng, Artur Cavaco-paulo, Rong Li, Yuzheng Lu, Xinming Zheng, Ruijuan Han, Chaoran Meng
-
Patent number: 11939616Abstract: The present disclosure provides, inter alia, compositions and methods for enforcing a pattern of cell surface fucosylated lactosaminyl glycans on a human cell. In certain embodiments, the compositions and/or methods utilize one or more members of the ?(1,3)-fucosyltransferase family. In certain embodiments, a process for custom-modifying a fucosylated lactosaminyl glycan on a human cell is disclosed.Type: GrantFiled: September 22, 2020Date of Patent: March 26, 2024Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: Robert Sackstein
-
Patent number: 11939613Abstract: The present disclosure relates to the production of cannabinoids in yeast. In as aspect there is provided a genetically modified yeast comprising: one or more GPP producing genes and optionally, one or more GPP pathway genes; two or more olivetolic acid producing genes; one or more cannabinoid precursor or cannabinoid producing genes; one or more Hexanoyl-CoA producing genes, and at least 5% dry weight of fatty acids or fats.Type: GrantFiled: September 14, 2021Date of Patent: March 26, 2024Assignee: BIOMEDICAN, INC.Inventors: Maxim Mikheev, Difeng Gao
-
Patent number: 11926819Abstract: Provided are methods of adding a polymer of non-canonical nucleotides to the 3? end of a ribonucleic acid (RNA). In certain embodiments, the methods comprise combining an RNA, a polynucleotide-3? nucleotidyl transferase, and non-canonical nucleotides, in a reaction mixture under conditions in which the polynucleotide-3? nucleotidyl transferase adds a polymer of the non-canonical nucleotides to the 3? end of the RNA. Such methods may further include analyzing the RNA using a nanopore. According to some embodiments, the methods include identifying the polymer of non-canonical nucleotides added to the 3? end of the RNA, and determining the junction between the 3? end of the RNA and the polymer of non-canonical nucleotides to identify the 3? end of the RNA. Kits that find use, e.g., in practicing the methods of the present disclosure are also provided.Type: GrantFiled: May 28, 2020Date of Patent: March 12, 2024Assignee: The Regents of the University of CaliforniaInventors: Manuel Ares, Logan Mulroney, Jenny Vo, Mark Akeson
-
Patent number: 11913033Abstract: The present invention is directed to nucleic acid molecules which encode novel luciferases, functional fragments thereof, homologs and mutants, as well as to proteins encoded by said nucleic acids. The nucleic acid molecules of interest are isolated from fungi or obtained by genetic engineering methods. Also, host cells, stable cell lines and transgenic organisms comprising said nucleic acid molecules are provided. In addition, antibodies specific to the proteins of the present invention are provided. Said proteins and nucleic acids are used in many applications and methods, in particular, in labelling organisms, cells, cellular organelles, or proteins. Also, said protein and nucleotide compositions are used in methods for detecting protein-protein interactions, for testing promoter activity under various conditions. Finally, provided are kits for the use of proteins and nucleic acids of the present invention in the diversity of methods and applications.Type: GrantFiled: December 6, 2017Date of Patent: February 27, 2024Assignee: Light Bio, Inc.Inventor: Il'ya Viktorovich Yampol'skiy
-
Patent number: 11905541Abstract: The present invention is directed to methods and kits for template-free enzymatic synthesis of polynucleotides that include or enable a step of efficiently cleaving the polynucleotide products from its initiator using an endonuclease V activity and initiator with a 3?-penultimate deoxyinosine.Type: GrantFiled: June 10, 2022Date of Patent: February 20, 2024Assignee: DNA Script SASInventor: Sandrine Creton
-
Patent number: 11899021Abstract: Provided herein are systems and methods for characterizing target/ligand engagement. In particular, luciferase-labeled polypeptide targets are used to detect or quantify target/ligand engagement (e.g., within a cell or cell lysate).Type: GrantFiled: January 4, 2023Date of Patent: February 13, 2024Assignee: Promega CorporationInventors: Melanie Dart, Lance P. Encell, Thomas Kirkland, Thomas Machleidt, Matthew Robers, Brock F. Binkowski, Keith Wood, Ce Shi
-
Patent number: 11891645Abstract: The present invention relates to serine protease variants, having improved properties compared to the parent protease, in particular variants of a serine protease derived from a strain of Meripilus giganteus belonging to the S53 family. The varinats according to the invention have in particular increased stability, e.g., increased thermo-stability, increased specific activity, and/or increased expression levels, compared to the parent protease. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: GrantFiled: July 14, 2017Date of Patent: February 6, 2024Assignee: NOVOZYMES A/SInventors: Dorte M. K. Klitgaard, Roland Alexander Pache, Martin Gudman, Anders G. Sandström
-
Patent number: 11891634Abstract: Disclosed herein are systems, methods, and compositions for rapidly and reversibly destabilizing a target protein in vitro or in vivo, in the presence or absence of a cell-permeable, synthetic molecule or ligand.Type: GrantFiled: June 22, 2018Date of Patent: February 6, 2024Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Thomas J. Wandless, Ling-Chun Chen, Yusaku Miyamae
-
Patent number: 11884954Abstract: A protein complex based on DNA enzymes of an E family of Escherichia coli and an application thereof in artificial protein scaffolds are provided. The protein complex includes one or more of interaction pairs formed by a CL2 protein and an Im2 protein, a CL7 protein and an Im7 protein, a CL8 protein and an Im8 protein, or a CL9 protein and an Im9 protein. By protein engineering of a carboxyl terminus DNase domain of the DNA enzymes CE2, CE7, CE8 and CE9, mutants that lose DNA enzyme activity but still retain the ultra-high affinity with the corresponding Im protein are obtained, and protein interaction pairs CL2/Im2, CL7/Im7, CL8/Im8 and CL9/Im9 are constructed. These protein interaction pairs have properties of heat resistance, high affinity, high specificity, small molecular weight, fast assembly speed, etc. Based on this, an artificial protein scaffold is constructed for the construction of artificial multienzyme complexes.Type: GrantFiled: December 29, 2022Date of Patent: January 30, 2024Assignee: Hubel UniversityInventors: Lixin Ma, Chao Zhai, Jun Yang, Fei Wang
-
Patent number: 11884927Abstract: This invention provides compositions and methods for providing high product yield of transgenes expressed in cyanobacteria and microalgae.Type: GrantFiled: December 11, 2020Date of Patent: January 30, 2024Assignee: The Regents of the University of CaliforniaInventors: Anastasios Melis, Cinzia Formighieri
-
Patent number: 11884928Abstract: The invention provides methods for genetically engineering Kluyveromyces. The methods can be used to genetically engineer Kluyveromyces to produce and secrete full-length antibodies or antibody fragments. The invention also provides methods for production and secretion of antibodies.Type: GrantFiled: September 12, 2018Date of Patent: January 30, 2024Assignee: Amyris, Inc.Inventor: Yoseph Tsegaye
-
Patent number: 11873479Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.Type: GrantFiled: April 29, 2021Date of Patent: January 16, 2024Assignee: SEATTLE CHILDREN'S RESEARCH INSTITUTEInventors: Andrew M. Scharenberg, Michael T. Certo, Kamila Sabina Gwiazda
-
Patent number: 11873518Abstract: This disclosure relates to modified tryptophan synthase and more particularly to modified beta-subunits of tryptophan synthase. The disclosure further relates to cells expressing such modified subunits and methods of producing non-canonical amino acids.Type: GrantFiled: April 19, 2022Date of Patent: January 16, 2024Assignee: California Institute of TechnologyInventors: David K. Romney, Javier Murciano Calles, Jori E. Wehrmuller
-
Patent number: 11866756Abstract: The embodiments of the present disclosure provides a method of co-producing erythritol and arabinose by using a xylose mother liquor, wherein an extract and a raffinate are obtained by separating the xylose mother liquor through a first chromatography, the extract is configured to prepare crystallized xylose, the raffinate and the liquid glucose or crystallized glucose are blended and erythritol is produced by using a Yarrowia lipolytica with high osmotolerant and a high conversion rate. erythritol crystals are obtained by centrifugation and crystallization first by using characteristics of low solubility degree and easy crystallization of the erythritol, the arabinose raffinate having a high content of arabinose is obtained by separating a centrifuged erythritol mother liquor through a second chromatography, and arabinose crystals are obtained based on the arabinose raffinate.Type: GrantFiled: July 18, 2023Date of Patent: January 9, 2024Assignee: ZHEJIANG HUAKANG PHARMACEUTICAL CO., LTD.Inventors: Aijuan Wu, Jiaxing Luo, Changhui Hu, Mingqian Yang, Chengjun Liao, Yi Zheng, Shuncheng Fang, Mian Li